Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in J Clin Invest

Retrieve available abstracts of 15 articles:
HTML format
Text format



Single Articles


    May 2017
  1. OLVEDY M, Tisserand JC, Luciani F, Boeckx B, et al
    Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.
    J Clin Invest. 2017 May 2. pii: 91291. doi: 10.1172/JCI91291.
    PubMed     Text format     Abstract available


    September 2016
  2. JANOWSKI AM, Colegio OR, Hornick EE, McNiff JM, et al
    NLRC4 suppresses melanoma tumor progression independently of inflammasome activation.
    J Clin Invest. 2016 Sep 12. pii: 86953. doi: 10.1172/JCI86953.
    PubMed     Text format     Abstract available


    August 2016
  3. LUND AW, Wagner M, Fankhauser M, Steinskog ES, et al
    Lymphatic vessels regulate immune microenvironments in human and murine melanoma.
    J Clin Invest. 2016 Aug 15. pii: 79434. doi: 10.1172/JCI79434.
    PubMed     Text format     Abstract available


  4. DAUD AI, Loo K, Pauli ML, Sanchez-Rodriguez R, et al
    Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
    J Clin Invest. 2016 Aug 15. pii: 87324. doi: 10.1172/JCI87324.
    PubMed     Text format     Abstract available


    February 2016
  5. JACQUELOT N, Enot DP, Flament C, Vimond N, et al
    Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.
    J Clin Invest. 2016 Feb 8. pii: 80071. doi: 10.1172/JCI80071.
    PubMed     Text format     Abstract available


    January 2016
  6. LEISEGANG M, Kammertoens T, Uckert W, Blankenstein T, et al
    Targeting human melanoma neoantigens by T cell receptor gene therapy.
    J Clin Invest. 2016 Jan 25. pii: 83465. doi: 10.1172/JCI83465.
    PubMed     Text format     Abstract available


  7. KLEBANOFF CA, Scott CD, Leonardi AJ, Yamamoto TN, et al
    Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.
    J Clin Invest. 2016;126:318-34.
    PubMed     Text format     Abstract available


  8. DEWAELE M, Tabaglio T, Willekens K, Bezzi M, et al
    Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.
    J Clin Invest. 2016;126:68-84.
    PubMed     Text format     Abstract available


    November 2015
  9. KNIGHT DA, Ngiow SF, Li M, Parmenter T, et al
    Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
    J Clin Invest. 2015 Nov 23. pii: 84828. doi: 10.1172/JCI84828.
    PubMed     Text format    


  10. KURTULUS S, Sakuishi K, Ngiow SF, Joller N, et al
    TIGIT predominantly regulates the immune response via regulatory T cells.
    J Clin Invest. 2015;125:4053-62.
    PubMed     Text format     Abstract available


    October 2015
  11. COHEN CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, et al
    Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.
    J Clin Invest. 2015;125:3981-91.
    PubMed     Text format     Abstract available


  12. HURST JH
    Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award.
    J Clin Invest. 2015;125:3732-6.
    PubMed     Text format    


    September 2015
  13. BUCHBINDER E, Hodi FS
    Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
    J Clin Invest. 2015;125:3377-83.
    PubMed     Text format     Abstract available


    May 2015
  14. POLLIZZI KN, Patel CH, Sun IH, Oh MH, et al
    mTORC1 and mTORC2 selectively regulate CD8(+) T cell differentiation.
    J Clin Invest. 2015;125:2090-108.
    PubMed     Text format     Abstract available


  15. MCCRACKEN MN, Vatakis DN, Dixit D, McLaughlin J, et al
    Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging.
    J Clin Invest. 2015;125:1815-26.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: